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Abstract
In the era of highly effective direct acting antiviral 
(DAA) drugs for the treatment of chronic hepatitis C 
(CHC) infection, where eradication is almost ensured 
with minimal side effects, all hepatitis C carriers should 
benefit theoretically. In the real world setting however, 
only a small proportion will benefit at this time point 
due to the multiple barriers to accessing therapy. Given 
that universal treatment is unlikely, treatment with 
DAAs will likely be restricted to those with the highest 
health benefits, and for those who can afford the high 
expense of a treatment course. Those with the highest 
unmet needs include those who have failed previous 
interferon-based therapy or who are interferon-ineligible 
with evidence of active disease, those with advance liver 
disease, and those with recurrence of hepatitis C after 
liver transplantation. In the future, the focus should be 
on increasing access to treatment for those infected 
with CHC. 
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Core tip: Chronic hepatitis C has become an easily 
curable disease with new direct acting antivirals (DAAs). 
However, due to multiple barriers to therapy, only 
those with highest unmet clinical needs including those 
with prior treatment failure, cirrhosis, and post-liver 
transplant, will likely receive therapy. DAAs have been 
shown to be highly efficacious in these groups. 
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INTRODUCTION
An estimated 170 million people worldwide are 
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chronically infected with the hepatitis C virus (HCV), 
affecting 2-3 percent of the world population, and 
constituting a major health burden globally[1,2]. For those 
with chronic hepatitis C (CHC), approximately 20% 
will progress to the development of liver cirrhosis[3]. 
This process usually takes several decades to occur 
although disease progression can be accelerated by 
the presence of co-existing liver disease[4], co-infection 
with other viruses such as human immunodeficiency 
virus[5-8], and also with alcohol intake[9-11]. Once cirrhosis 
is established, further complications may occur with liver 
decompensation and the development of hepatocellular 
carcinoma (HCC)[12]. In fact, the history of HCV is 
relatively short, with the discovery of the blood-borne 
virus in 1989 just over 25 years ago. Major routes of 
transmission include transfusion of unscreened conta-
minated blood products[13], and persons who inject drugs 
using contaminated drug paraphernalia[14]. 
EVOLUTION OF ANTIVIRAL THERAPY 
FOR CHC
In the early 1990s, standard interferon (IFN) alpha-2b 
was used to treat CHC infection. However, the curative 
rate with standard IFN monotherapy was dismal, 
with only approximately 15% achieving a sustained 
virological response (SVR)[15,16]. The addition of ribavirin 
enhanced the SVR to 33% and 41% for 24 and 48 wk of 
therapy respectively[17-19]. The subsequent introduction 
of pegylated IFN (Peg-IFN) in combination with ribavirin 
(RBV) improved the SVR rate to an estimated 50%[20,21]. 
The length of treatment ranged from 24-48 wk, and 
together with the SVR, was dependent on the genotype 
of the HCV[22]. Despite significant side effects, the 
modest SVR rate, the need for parenteral injections, and 
prolonged duration of therapy, Peg-IFN and RBV (PR) 
remained the standard of care for over a decade from 
the turn of the new millennium.
Over the last several years, there has been an 
exponential increase in therapeutic agents approved 
for CHC infection. These agents, collectively known as 
direct acting antivirals (DAAs), work by inhibiting specific 
stages of the HCV replication cycle. Classes of drugs 
include NS3/4A protease inhibitors, non-nucleoside 
polymerase inhibitors, NS5B nucleos(t)ide polymerase 
inhibitors, NS5A inhibitors, and cyclophilin inhibitors. 
In 2011, boceprevir and telaprevir were approved for 
the treatment of GT1 patients, improving the SVR 
to 68%-75% for treatment-naive patients[23,24], and 
51%-59% in treatment-experienced patients[25,26]. 
Despite the modest improvement, these first gene-
ration DAAs still required the use of PR, resulting 
in a complicated treatment regimen and potential 
for significant side effects. In 2013, sofosbuvir and 
simeprevir were approved. The use of simeprevir or 
sofosbuvir with PR therapy for 12 wk achieved an SVR of 
approximately 80% and 90% respectively[27-29]. An all-
oral combination of simeprevir and sofosbuvir achieved 
an overall SVR12 rate of 92%, proving evidence of 
the efficacy of an all-oral regimen[30]. In 2014, 3 all-
oral combination regimens were approved, including 
sofosbuvir + simeprevir, sofosbuvir + ledipasvir, and 
ombitasvir + paritaprevir + ritonavir + dasabuvir. All 3 
regimens were demonstrated to be highly effective, with 
SVR rates approaching 100%[31-35].
Within a space of a few years, the treatment of CHC 
has seen a dramatic shift in paradigm. CHC infection 
has emerged from a disease that has been difficult 
to cure with prolonged parenteral therapy to one that 
is easily curable with a short duration of oral antiviral 
therapy with minimal side effects. 
WHO WILL BENEFIT?
Given the high SVR rates achieved, and the favorable 
side effects profile of DAAs, it stands to reason that all 
CHC carriers should benefit from these newly approved 
all-oral combination DAA therapies. Moreover, with the 
high cure rates observed, for the first time, there is a 
glimpse of opportunity to eradicate HCV completely. In 
reality however, only a small fraction of CHC patients 
will likely receive DAAs at this time point, as shown 
in Figure 1. This is due to the fact that there are multi-
ple barriers to HCV treatments that currently exist, 
precluding patients from receiving the best treatment 
available[36,37]. The barriers most inherent to DAAs 
include the availability of these new agents and the high 
cost associated with a treatment course[38]. Until these 
become widely available, and at an affordable cost, the 
benefits of DAAs will likely be restricted to those with 
the highest unmet needs. These include patients who 
have failed previous IFN-based therapies with evidence 
of disease progression, those who are ineligible for IFN 
therapy with progressive disease, those with established 
cirrhosis, those on the liver transplant waiting list, and 
those who have had a liver transplant (Figure 1).
Patients who have failed previous IFN-based therapies
For those who have failed previous IFN-based therapies, 
combination DAAs offers the best chance of achieving 
SVR. In the COSMOS trial of 80 HCV GT1 patients 
who were null responders treated with simeprevir and 
sofosbuvir +/- ribavirin for 24 wk, the SVR achieved 
was 90%[30]. A trial (the SAPPHIRE 2 study) of 297 
HCV GT1 patients without cirrhosis who had failed PR 
therapy and treated with 12 wk of ritonavir-boosted 
paritaprevir + ombitasvir + dasabuvir + RBV resulted 
in an overall SVR rate of 96.3%[39]. In the ION-2 
study, 440 HCV GT1 previously treated patients given 
sofosbuvir + ledipasvir +/- RBV Ⅰ for 12-24 wk resulted 
in a SVR rate of ≥ 94%[31]. Despite previously failing 
to respond to IFN-based regimens, combinations DAAs 
have been demonstrated to be highly effective for this 
group of patients.
Patients ineligible for IFN therapy
There may be many different reasons as to why patients 
may be ineligible for IFN-based treatment. These include 
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those who are intolerant to IFN or have hypersensitivity 
to polyethylene glycol, have underlying autoimmune 
hepatitis or other severe autoimmune disorders[40,41], 
history of significant psychiatric disorder such as 
depression[42], and pre-existing cardiac disease[43]. 
Those patients with significant anemia, neutropenia, 
or thrombocytopenia may also be contra-indicated, as 
therapy with IFN can potentially compound the pre-
existing cytopenic state[44-46]. Patients with established 
severe liver disease are also contra-indicated for IFN-
based therapy, as there is a risk of decompensation and 
liver failure with the use of IFN[47]. 
Therefore, for those with evidence of active hepatitis 
and disease progression, and whom IFN is contra-
indicated or tolerated poorly, the use of combination 
DAAs is the only therapeutic option in this setting.  
Patients with established cirrhosis
As mentioned previously, those patients with established 
cirrhosis, especially with evidence of advance liver 
disease (Child Pugh B or C), are not eligible for IFN-based 
therapy as there is an increase risk of precipitating liver 
decompensation and failure[48]. Prior to the availability 
of all-oral combination of DAAs regimen, there was 
no specific antiviral therapy available for this group. 
Management of these patients with evidence of active 
hepatitis and disease progression was often frustrating 
for clinicians where the only outcome was either decom-
pensation leading to death or liver transplantation. 
Ironically, this group of patient perhaps is the group that 
would need effective antiviral therapy the most. 
Several studies have shown that DAAs are highly 
effective in patients with established cirrhosis. In the 
TURQUOISE Ⅱ trial of 380 compensated cirrhotic 
patients infected with HCV genotype 1 using ritonavir-
boosted paritaprevir + ombitasvir + dasabuvir + RBV, 
the SVR rate was noted to be 92% and 96% with 12 
and 24 wk of treatment respectively[49]. A multicenter 
double blind study using ledipasvir + sofosbuvir for 
24 wk and ledipasvir + sofosbuvir + RBV for 12 wk 
in compensated HCV genotype 1 patients, the SVR12 
rates were 97% and 96% respectively[50]. In the 
SOLAR-2 study of 108 decompensated patients with 
HCV GT 1/4, treatment with ledipasvir + sofosbuvir + 
RBV for 12 and 24 wk were associated with a SVR rate 
of 87% and 89% respectively[51].
Patients on the liver transplant waiting list
As hepatitis C recurrence is universal for those patients 
who are viremic at the time of liver transplantation, 
there is enormous impetus to eradicate or treat HCV 
prior to transplantation[52-54]. The indications for liver 
transplantation for CHC patients include those with 
decompensated cirrhosis and those with HCC[55]. For 
those with decompensated cirrhosis, as discussed in 
the previous section, treatments using DAAs has been 
shown to be effective. There are several rationales for 
treating wait-listed patients. Firstly, there is a theoretical 
opportunity that for those that achieve SVR, liver 
synthetic function may be restored sufficiently to the 
point whereby liver transplantation is no longer required 
(similar to that observed for patients with chronic 
hepatitis B)[56,57]. Secondly, achieving SVR or complete 
viral suppression will prevent or reduce the rate of 
disease progression and further decompensation[58,59]. 
Thirdly, by achieving viral suppression or SVR prior to
liver transplantation, the recurrence rate after liver 
transplantation will be significantly improved, and even 
prevented for those who achieve SVR prior to their liver
transplant[60]. In a phase Ⅱ open-label study of 61 
patients with HCV of any genotype and compensated 
cirrhosis with HCC were treated up to 48 wk of 
sofosbuvir + RBV before liver transplantation. Of these, 
43 had undetectable HCV RNA at the time of trans-
plantation, of which 30 (70%) had virological response 
at 12 wk post transplant. The recurrence was related 
inversely to the number of consecutive days of undetec-
table HCV RNA before transplantation[61]. There has also 
been reported case of decompensated patient improving 
to the point of being delisted after treatment with 
sofosbuvir and ribavirin for 24 wk[62].
Patients after liver transplantation
For patients with recurrent hepatitis C after liver 
transplantation, the disease progression is accelerated, 
with approximately 20% developing graft cirrhosis by 
5 years[63-66]. The use of long-term immunosuppression 
or large doses of pulse steroid during episodes of acute 
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Figure 1  Current treatment model in the era of direct acting antivirals for chronic hepatitis C with respect to the patients who will benefit.
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of patients are being treated.
Due to the high cost of DAAs, questions are raised 
regarding the cost-effectiveness of these new regimens. 
There are now several studies demonstrating that 
the new DAAs are cost-effective across a wide range 
of patients, including those with early disease[82-84]. 
However, in the real world, with millions of eligible 
patients for antiviral therapy, the cost of therapy would 
be prohibitive. The previous sections have identified 
subsets of chronic HCV carriers with perhaps the highest 
unmet needs currently, and with the highest health 
benefit to cost ratio. For this group of patients, the cost 
of managing decompensated liver cirrhosis or liver 
transplantation far exceeds the cost of a course of DAAs.
CONCLUSION
The introduction of DAAs over the last several years 
has revolutionized the treatment landscape for CHC 
infection. Currently, SVR can be achieved in almost all 
patients treated with combination all-oral regimens with 
minimal side effects. Therefore, these newly approved 
DAAs will certainly improve almost every aspect of 
patient outcome, but only for those who have access 
to treatment. Although the high costs remain a major 
hurdle for many, other barriers exist. These barriers 
include the lack of an effective screening strategy to 
identify all chronic HCV carriers, medical eligibility for 
therapy, stigmatization of HCV carriers, and also the 
attribution of the patient and health care provider. 
The possibility of treatment being available to all CHC 
subjects with complete eradication of HCV remains 
a distant prospect, and can only be achieved with 
universal screening of at-risk subjects, and making treat-
ment widely available and affordable to all (Figure 1). 
In the current review, those infected the CHC with the 
highest unmet needs are discussed. These are patients 
for whom treatment is likely to incur the highest health 
benefit. As treatment becomes increasingly affordable 
and more widely available, more patient groups will 
stand to benefit. In the era of highly effective DAAs 
where treatment efficacy is no longer an issue, the 
focus should now be on increasing access and removing 
barriers to therapy. 
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